Amedeo Smart

Free Medical Literature Service

 

Amedeo

Breast Cancer
  Free Subscription

Articles published in
Eur J Cancer
    April 2024
  1. COLOMBO I, Koster KL, Holer L, Haefliger S, et al
    TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16).
    Eur J Cancer. 2024;201:113588.
    >> Share

  2. BARTELS SAL, van Olmen JP, Scholten AN, Bekers EM, et al
    Real-world data on malignant and borderline phyllodes tumors of the breast: A population-based study of all 921 cases in the Netherlands (1989 -2020).
    Eur J Cancer. 2024;201:113924.
    >> Share

    March 2024
  3. ROUSSOT N, Constantin G, Desmoulins I, Bergeron A, et al
    Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
    Eur J Cancer. 2024;202:114037.
    >> Share

  4. UNTCH M, Perol D, Mayer EL, Cortes J, et al
    Disease-free survival as a surrogate for overall survival in HR+/HER2- early breast cancer: A correlation analysis.
    Eur J Cancer. 2024;202:113977.
    >> Share

    February 2024
  5. TARANTINO P, Ajari O, Graham N, Vincuilla J, et al
    Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer.
    Eur J Cancer. 2024;201:113920.
    >> Share

  6. YANG F, Liu G, Mao F, Zheng YC, et al
    Corrigendum to "Re: Pathologic complete responses, long-term outcomes, and recurrence patterns in HER2-low vs. HER2-zero breast cancer after neoadjuvant chemotherapy: Several issues about HER2 expression and neoadjuvant chemotherapy in breast cancer"
    Eur J Cancer. 2024 Feb 2:113559. doi: 10.1016/j.ejca.2024.113559.
    >> Share

    January 2024
  7. DIERAS V, Han HS, Wildiers H, Friedlander M, et al
    Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial.
    Eur J Cancer. 2024;200:113580.
    >> Share

  8. RUSAKIEWICZ S, Tyekucheva S, Tissot-Renaud S, Chaba K, et al
    Multiplexed high-throughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00.
    Eur J Cancer. 2024;200:113535.
    >> Share

  9. GIORGI ROSSI P, Mancuso P, Pattacini P, Campari C, et al
    Comparing accuracy of tomosynthesis plus digital mammography or synthetic 2D mammography in breast cancer screening: baseline results of the MAITA RCT consortium.
    Eur J Cancer. 2024;199:113553.
    >> Share

  10. TOLANEY SM, Guarneri V, Seo JH, Cruz J, et al
    Long-term patient-reported outcomes from monarchE: Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer.
    Eur J Cancer. 2024;199:113555.
    >> Share

  11. VALENZA C, De Pas TM, Gaeta A, Castellano G, et al
    Primary malignant phyllodes tumors of the breast: A retrospective analysis from a referral center.
    Eur J Cancer. 2024;196:113423.
    >> Share

    December 2023
  12. RUBIO IT, Marotti L, Biganzoli L, Aristei C, et al
    EUSOMA quality indicators for non-metastatic breast cancer: An update.
    Eur J Cancer. 2023;198:113500.
    >> Share

  13. FASCHING PA, Decker T, Hartkopf A, Nusch A, et al
    Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or
    Eur J Cancer. 2023;198:113480.
    >> Share

  14. JACOBS F, Molinelli C, Martins-Branco D, Marta GN, et al
    Progression-free survival assessment by local investigators versus blinded independent central review in randomized clinical trials in metastatic breast cancer: A systematic review and meta-analysis.
    Eur J Cancer. 2023;197:113478.
    >> Share

  15. MAKHLOUF S, Quinn C, Toss M, Alsaleem M, et al
    Quantitative expression of oestrogen receptor in breast cancer: Clinical and molecular significance.
    Eur J Cancer. 2023;197:113473.
    >> Share

  16. LORD SJ, Kiely BE, O'Connell DL, Daniels B, et al
    Characteristics and post-metastasis survival of recurrent metastatic breast cancer over time - An Australian population-based record linkage study, 2001-2016.
    Eur J Cancer. 2023;197:113468.
    >> Share

  17. MORGANTI S, Marra A, Gandini S, Ascione L, et al
    Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study.
    Eur J Cancer. 2023;195:113397.
    >> Share

    November 2023
  18. LEE DW, Jung KH, Lee KH, Park YH, et al
    Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): A randomized, open-label, multicenter, phase II trial.
    Eur J Cancer. 2023;197:113456.
    >> Share

  19. ARISTEI C, Tomatis M, Antonio Ponti, Marotti L, et al
    Treatment and outcomes in breast cancer patients: A cross section study from the EUSOMA breast centre network.
    Eur J Cancer. 2023;196:113438.
    >> Share

  20. ROY S, Lakritz S, Schreiber AR, Kuna EM, et al
    Major cardiovascular adverse events in older adults with early-stage triple-negative breast cancer treated with adjuvant taxane + anthracycline versus taxane-based chemotherapy regimens: A SEER-medicare study.
    Eur J Cancer. 2023;196:113426.
    >> Share

  21. GALVIN A, Courtinard C, Bouteiller F, Gourgou S, et al
    First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort.
    Eur J Cancer. 2023;196:113422.
    >> Share

  22. GARCIA-SAENZ JA, Marme F, Untch M, Bonnefoi H, et al
    Patient-reported outcomes in high-risk HR+ /HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPE(B) study.
    Eur J Cancer. 2023;196:113420.
    >> Share

    October 2023
  23. WANG Y, Broeks A, Giardiello D, Hauptmann M, et al
    External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naive women with node-negative breast cancer.
    Eur J Cancer. 2023;195:113401.
    >> Share

  24. MIGLIETTA F, Dieci MV, Giarratano T, Torri V, et al
    Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies.
    Eur J Cancer. 2023;195:113399.
    >> Share

  25. SCHMID P, Lipatov O, Im SA, Goncalves A, et al
    Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study.
    Eur J Cancer. 2023;195:113393.
    >> Share

  26. MARME F, Krieghoff-Henning E, Gerber B, Schmitt M, et al
    Deep learning to predict breast cancer sentinel lymph node status on INSEMA histological images.
    Eur J Cancer. 2023;195:113390.
    >> Share

  27. KIM SH, Im SA, Suh KJ, Lee KH, et al
    Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16).
    Eur J Cancer. 2023;195:113386.
    >> Share

  28. ATALLAH NM, Haque M, Quinn C, Toss MS, et al
    Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expression.
    Eur J Cancer. 2023;195:113371.
    >> Share

  29. SCHMITZ RSJM, Engelhardt EG, Gerritsma MA, Sondermeijer CMT, et al
    Active surveillance versus treatment in low-risk DCIS: Women's preferences in the LORD-trial.
    Eur J Cancer. 2023;192:113276.
    >> Share

    September 2023
  30. MARTINS-BRANCO D, Nader-Marta G, Molinelli C, Ameye L, et al
    Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: a systematic review and meta-analysis.
    Eur J Cancer. 2023;194:113358.
    >> Share

  31. SCHMIDT M, Nitz U, Reimer T, Schmatloch S, et al
    Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate - The ICE randomized clinical trial.
    Eur J Cancer. 2023;194:113324.
    >> Share

  32. PETRELLI F, Cavallone M, Dottorini L
    10 years or less of extended adjuvant endocrine therapy for postmenopausal breast cancer patients: A systematic review and network meta-analysis.
    Eur J Cancer. 2023;193:113322.
    >> Share

  33. MOUABBI JA, Raghavendra AS, Bassett RL Jr, Christgen M, et al
    Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma.
    Eur J Cancer. 2023;191:113250.
    >> Share

  34. WANG Y, Ali MA, Vallon-Christersson J, Humphreys K, et al
    Transcriptional intra-tumour heterogeneity predicted by deep learning in routine breast histopathology slides provides independent prognostic information.
    Eur J Cancer. 2023;191:112953.
    >> Share

    August 2023
  35. BALTUSSEN JC, Lemij AA, de Glas NA, Portielje JEA, et al
    Response to letter entitled: Re: Association between endocrine therapy and cognitive decline in older women with early breast cancer: Findings from the prospective CLIMB study.
    Eur J Cancer. 2023 Aug 10:113240. doi: 10.1016/j.ejca.2023.113240.
    >> Share

  36. CHEN H, Feng L
    Letter Re: Association between endocrine therapy and cognitive decline in older women with early breast cancer: Findings from the prospective CLIMB study.
    Eur J Cancer. 2023 Aug 5:113239. doi: 10.1016/j.ejca.2023.113239.
    >> Share

    July 2023
  37. VAN WALLE L, Verhoeven D, Marotti L, Ponti A, et al
    Trends and variation in treatment of early breast cancer in European certified breast centres: an EUSOMA-based analysis.
    Eur J Cancer. 2023;192:113244.
    >> Share

  38. VAN BAELEN K, Nguyen HL, Hamy-Petit AS, Richard F, et al
    Association of body mass index with clinicopathological features and survival in patients with primary invasive lobular breast cancer.
    Eur J Cancer. 2023;191:112988.
    >> Share

    June 2023
  39. KANG S, Lee SH, Lee HJ, Jeong H, et al
    Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancer.
    Eur J Cancer. 2023;191:112956.
    >> Share

  40. LEE JW, Oh H, You JY, Lee ES, et al
    Therapy-related myeloid neoplasm in early breast cancer patients treated with adjuvant chemotherapy.
    Eur J Cancer. 2023;191:112952.
    >> Share

  41. VALENZA C, Trapani D, Gandini S, Sposetti C, et al
    Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments.
    Eur J Cancer. 2023;190:112944.
    >> Share

  42. SCHETTINI F, Fontana A, Gattazzo F, Strina C, et al
    Faecal microbiota composition is related to response to CDK4/6-inhibitors in metastatic breast cancer: A prospective cross-sectional exploratory study.
    Eur J Cancer. 2023;191:112948.
    >> Share

  43. GRINDA T, Antoine A, Jacot W, Cottu PH, et al
    Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort.
    Eur J Cancer. 2023;189:112935.
    >> Share

  44. LIN T, Ding Z, Li N, Xu J, et al
    Retraction notice to "Seleno-cyclodextrin sensitizes human breast cancer cells to TRAIL-induced apoptosis through DR5 induction and NF-kappaB suppression" [Eur J Cancer., 47 (2011) 1890-1907, http://dx.doi.org/10.1016/j.ejca.2011.04.004].
    Eur J Cancer. 2023;186:222.
    >> Share

  45. LEONE JP, Graham N, Leone J, Tolaney SM, et al
    Estimating mortality in women with triple-negative breast cancer: The 'ESTIMATE triple-negative' tool.
    Eur J Cancer. 2023;189:112930.
    >> Share

    May 2023
  46. DESMOULINS I, Bellio H, Mejean N, Truntzer C, et al
    Intracranial response of brain metastases in patients with HER2-amplified breast cancer treated with trastuzumab-deruxtecan after failure of tucatinib-based therapy.
    Eur J Cancer. 2023;187:161-163.
    >> Share

  47. GEUKENS T, De Schepper M, Richard F, Maetens M, et al
    Intra-patient and inter-metastasis heterogeneity of HER2-low status in metastatic breast cancer.
    Eur J Cancer. 2023;188:152-160.
    >> Share

  48. BUCALO A, Conti G, Valentini V, Capalbo C, et al
    Male breast cancer risk associated with pathogenic variants in genes other than BRCA1/2: an Italian case-control study.
    Eur J Cancer. 2023;188:183-191.
    >> Share

    April 2023
  49. DEUTSCH TM, Pfob A, Brusniak K, Riedel F, et al
    Machine learning and patient-reported outcomes for longitudinal monitoring of disease progression in metastatic breast cancer: a multicenter, retrospective analysis.
    Eur J Cancer. 2023;188:111-121.
    >> Share

  50. VILLACAMPA G, Matikas A, Oliveira M, Prat A, et al
    Landscape of neoadjuvant therapy in HER2-positive breast cancer: a systematic review and network meta-analysis.
    Eur J Cancer. 2023 Apr 8:S0959-8049(23)00188-0. doi: 10.1016/j.ejca.2023.
    >> Share

  51. LEMIJ AA, de Glas NA, Derks MGM, Linthorst-Niers EMH, et al
    Mental health outcomes in older breast cancer survivors: Five-year follow-up from the CLIMB study.
    Eur J Cancer. 2023;187:87-95.
    >> Share

    March 2023
  52. CARDOSO F, McCartney A, Ponti A, Marotti L, et al
    European Society of Breast Cancer Specialists/Advanced Breast Cancer Global Alliance quality indicators for metastatic breast cancer care.
    Eur J Cancer. 2023;187:105-113.
    >> Share

  53. TRILLO P, Sandoval J, Trapani D, Nicolo E, et al
    Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases.
    Eur J Cancer. 2023;185:119-130.
    >> Share

  54. MALORNI L, Bianchini G, Caputo R, Zambelli A, et al
    Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial.
    Eur J Cancer. 2023;186:1-11.
    >> Share

  55. SCHMIDT MK, Kelly JE, Bredart A, Cameron DA, et al
    EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy.
    Eur J Cancer. 2023;181:79-91.
    >> Share

    February 2023
  56. ROY S, Lakritz S, Schreiber AR, Molina E, et al
    Clinical outcomes of adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens in older adults with node-positive, triple-negative breast cancer: A SEER-Medicare study.
    Eur J Cancer. 2023;185:69-82.
    >> Share

  57. BALTUSSEN JC, Derks MGM, Lemij AA, de Glas NA, et al
    Association between endocrine therapy and cognitive decline in older women with early breast cancer: Findings from the prospective CLIMB study.
    Eur J Cancer. 2023;185:1-10.
    >> Share

  58. WANG J, Cai L, Song Y, Sun T, et al
    Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study).
    Eur J Cancer. 2023;184:73-82.
    >> Share

  59. ROBSON ME, Im SA, Senkus E, Xu B, et al
    OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
    Eur J Cancer. 2023;184:39-47.
    >> Share

  60. HOLMES FA, Moy B, Delaloge S, Chia SKL, et al
    Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.
    Eur J Cancer. 2023;184:48-59.
    >> Share

    January 2023
  61. FASCHING PA, Hein A, Kolberg HC, Haberle L, et al
    Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer - A single-arm phase II trial (NeoImmunoboost, AGO-B-041).
    Eur J Cancer. 2023;184:1-9.
    >> Share

    December 2022
  62. YANG F, Liu G, Mao F, Zheng YC, et al
    Re: Pathologic complete responses, long-term outcomes, and recurrence patterns in HER2-low vs. HER2-zero breast cancer after neoadjuvant chemotherapy: Several issues about HER2 expression and neoadjuvant chemotherapy in breast cancer.
    Eur J Cancer. 2022 Dec 27:S0959-8049(22)01763-4. doi: 10.1016/j.ejca.2022.
    >> Share

  63. NUCIFORO P, Townend J, Piccart MJ, Fielding S, et al
    Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.
    Eur J Cancer. 2022;181:92-101.
    >> Share

  64. KANG S, Kim SB
    Response to letter to the editor re: Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy.
    Eur J Cancer. 2022 Dec 16:S0959-8049(22)01764-6. doi: 10.1016/j.ejca.2022.
    >> Share

  65. BELTRAN-BLESS AA, Clemons MJ, Fesl C, Greil R, et al
    Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12.
    Eur J Cancer. 2022;180:108-116.
    >> Share

  66. CABASAG CJ, Vignat J, Ferlay J, Arndt V, et al
    The preventability of cancer in Europe: A quantitative assessment of avoidable cancer cases across 17 cancer sites and 38 countries in 2020.
    Eur J Cancer. 2022;177:15-24.
    >> Share

    November 2022
  67. BRAVACCINI S, Puccetti M, Maltoni R
    Re: "Evolution of low HER2 expression between early and advanced-stage breast cancer".
    Eur J Cancer. 2022 Nov 13. pii: S0959-8049(22)00801.
    >> Share

  68. JIAO Y, Truong T, Eon-Marchais S, Mebirouk N, et al
    Association and performance of polygenic risk scores for breast cancer among French women presenting or not a familial predisposition to the disease.
    Eur J Cancer. 2022;179:76-86.
    >> Share

  69. TARANTINO P, Nicolo E, Curigliano G
    Response to letter entitled: Re: "Evolution of low HER2 expression between early and advanced-stage breast cancer".
    Eur J Cancer. 2022 Nov 9. pii: S0959-8049(22)00802.
    >> Share

    October 2022
  70. LOIBL S, Loirat D, Tolaney SM, Punie K, et al
    Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer.
    Eur J Cancer. 2022;178:23-33.
    >> Share

  71. VAN DAM P, Tomatis M, Ponti A, Marotti L, et al
    The impact of the SARS-COV-2 pandemic on the quality of breast cancer care in EUSOMA-certified breast centres.
    Eur J Cancer. 2022;177:72-79.
    >> Share

  72. GHANNAM Y, Di Meglio A, Sarrade T, Jacquet A, et al
    Impact of radiation therapy on fatigue at 1 year in breast cancer survivors in the prospective multicentre CANcer TOxicity cohort.
    Eur J Cancer. 2022;177:143-153.
    >> Share

  73. SWAIN SM, Tan AR, Gianni L, Kuemmel S, et al
    Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer.
    Eur J Cancer. 2022;178:70-81.
    >> Share

  74. HUANG M, O'Shaughnessy J, Haiderali A, Pan W, et al
    Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1.
    Eur J Cancer. 2022;177:45-52.
    >> Share

  75. TARANTINO P, Niman SM, Erick TK, Priedigkeit N, et al
    HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implications.
    Eur J Cancer. 2022;174:277-286.
    >> Share

  76. VILLACAMPA G, Falato C, Pare L, Hernando C, et al
    Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial.
    Eur J Cancer. 2022;174:232-242.
    >> Share

  77. M A, S C, J F, C L, et al
    Incidence and Outcome of Breast Sarcomas in England (2013-2018): An analysis from the National Cancer Registration and Analysis Service.
    Eur J Cancer. 2022;174:48-56.
    >> Share

  78. HOUVENAEGHEL G, de Nonneville A, Cohen M, Classe JM, et al
    Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a retrospective study.
    Eur J Cancer. 2022;176:58-69.
    >> Share

    September 2022
  79. KANG S, Lee SH, Lee HJ, Jeong H, et al
    Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy.
    Eur J Cancer. 2022;176:30-40.
    >> Share

  80. JIANG H, Ouyang Q, Yin Y, Tong Z, et al
    Proxalutamide in patients with AR-positive metastatic breast cancer: Results from an open-label multicentre phase Ib study and biomarker analysis.
    Eur J Cancer. 2022;176:1-12.
    >> Share

  81. PFOB A, Sidey-Gibbons C, Barr RG, Duda V, et al
    Intelligent multi-modal shear wave elastography to reduce unnecessary biopsies in breast cancer diagnosis (INSPiRED 002): a retrospective, international, multicentre analysis.
    Eur J Cancer. 2022;177:1-14.
    >> Share

  82. XU B, Hu X, Li W, Sun T, et al
    Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4.
    Eur J Cancer. 2022;175:236-245.
    >> Share

  83. BAEZ-NAVARRO X, Salgado R, Denkert C, Lennerz JK, et al
    Selecting patients with HER2-low breast cancer: Getting out of the tangle.
    Eur J Cancer. 2022;175:187-192.
    >> Share

  84. VLIEK SB, Hilbers FS, Jager A, Retel VP, et al
    Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancer.
    Eur J Cancer. 2022;175:169-179.
    >> Share

  85. KREGTING LM, Olthof EMG, Breekveldt ECH, Aitken CA, et al
    Concurrent participation in breast, cervical, and colorectal cancer screening in the Netherlands.
    Eur J Cancer. 2022;175:180-186.
    >> Share

  86. GROOTES I, Keeman R, Blows FM, Milne RL, et al
    Incorporating progesterone receptor expression into the PREDICT breast prognostic model.
    Eur J Cancer. 2022;173:178-193.
    >> Share

  87. DE BOER AZ, Bastiaannet E, Schetelig J, de Glas NA, et al
    Breast cancer mortality of older patients with and without recurrence analysed by novel multi-state models.
    Eur J Cancer. 2022;174:212-220.
    >> Share

  88. REINERT T, Goncalves AC, de Resende CAA, Barrios CH, et al
    Implications of the PEARL trial from the low- to middle-income countries' perspectives.
    Eur J Cancer. 2022;173:30-32.
    >> Share

    August 2022
  89. CHEN SY, Sun GY, Tang Y, Jing H, et al
    Timing of postmastectomy radiotherapy following adjuvant chemotherapy for high-risk breast cancer: A post hoc analysis of a randomised controlled clinical trial.
    Eur J Cancer. 2022;174:153-164.
    >> Share

  90. GOLDRAT O, De Cooman M, Mailliez A, Delbaere A, et al
    Efficacy and safety of controlled ovarian hyperstimulation with or without letrozole for fertility preservation in breast cancer patients: A multicenter retrospective study.
    Eur J Cancer. 2022;174:134-141.
    >> Share

  91. KARSTEN MM, Roehle R, Albers S, Pross T, et al
    Corrigendum to 'Real-world reference scores for EORTC QLQ-C30 and EORTC QLQ-BR23 in early breast cancer patients [European Journal of Cancer 163 (2022) 128-139].
    Eur J Cancer. 2022 Aug 12. pii: S0959-8049(22)00403.
    >> Share

  92. GIORGI ROSSI P
    What a woman needs to know about overdiagnosis to decide about breast cancer screening.
    Eur J Cancer. 2022 Aug 5. pii: S0959-8049(22)00408.
    >> Share

    July 2022
  93. ANDERSON RA, Lambertini M, Hall PS, Wallace WH, et al
    Survival after breast cancer in women with a subsequent live birth: Influence of age at diagnosis and interval to subsequent pregnancy.
    Eur J Cancer. 2022;173:113-122.
    >> Share

  94. LEONE JP, Graham N, Tolaney SM, Leone BA, et al
    Estimating long-term mortality in women with hormone receptor-positive breast cancer: The 'ESTIMATE' tool.
    Eur J Cancer. 2022;173:20-29.
    >> Share

  95. ALMSTEDT K, Heimes AS, Kappenberg F, Battista MJ, et al
    Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer.
    Eur J Cancer. 2022;173:10-19.
    >> Share

  96. DING L, Poelhekken K, Greuter MJW, Truyen I, et al
    Overdiagnosis of invasive breast cancer in population-based breast cancer screening: A short- and long-term perspective.
    Eur J Cancer. 2022;173:1-9.
    >> Share

  97. BUDDE A, Baust K, Weinhold L, Bernstein M, et al
    Linking EORTC QLQ-C-30 and PedsQL/PEDQOL physical functioning scores in patients with osteosarcoma.
    Eur J Cancer. 2022;170:209-235.
    >> Share

    June 2022
  98. BATTISTI NML, De Glas N, Soto-Perez-de-Celis E, Liposits G, et al
    Chemotherapy and gene expression profiling in older early luminal breast cancer patients: An International Society of Geriatric Oncology systematic review.
    Eur J Cancer. 2022;172:158-170.
    >> Share

  99. ESTEVES F, Xavier JM, Ford AM, Rocha C, et al
    Germline allelic expression of genes at 17q22 locus associates with risk of breast cancer.
    Eur J Cancer. 2022;172:146-157.
    >> Share

  100. BATTISTI NML, Smith IE
    Preventing late recurrence in hormone receptor-positive early breast cancer: a review.
    Eur J Cancer. 2022;172:53-64.
    >> Share

  101. YAMADA A, Hayashi N, Kumamaru H, Nagahashi M, et al
    Prognostic impact of postoperative radiotherapy in patients with breast cancer and with pT1-2 and 1-3 lymph node metastases: A retrospective cohort study based on the Japanese Breast Cancer Registry.
    Eur J Cancer. 2022;172:31-40.
    >> Share

  102. OZAKI Y, Tsurutani J, Mukohara T, Iwasa T, et al
    Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B).
    Eur J Cancer. 2022;171:193-202.
    >> Share

  103. MULLER V, Hein A, Hartkopf AD, Fasching PA, et al
    Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry.
    Eur J Cancer. 2022;172:13-21.
    >> Share

  104. ZHANG J, Gao HF, Yang C, Zhu T, et al
    Prevention of taxane-associated acute pain syndrome with etoricoxib for patients with breast cancer: A phase II randomised trial.
    Eur J Cancer. 2022;171:150-160.
    >> Share

  105. VAN BERGE HENEGOUWEN JM, Jebbink M, Hoes LR, van der Wijngaart H, et al
    Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer.
    Eur J Cancer. 2022;171:114-123.
    >> Share

  106. ALTUNDAG K
    Re: Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study: Higher visceral tumour burden and weak estrogen rece
    Eur J Cancer. 2022;171:43.
    >> Share

  107. HEIMOVAARA JH, Boere IA, de Haan J, van Calsteren K, et al
    Ten-year experience of a national multidisciplinary tumour board for cancer and pregnancy in the Netherlands.
    Eur J Cancer. 2022;171:13-21.
    >> Share

  108. SALGADO R, Fineberg S, De Caluwe A, de Azambuja E, et al
    Tumour infiltrating lymphocytes and ductal carcinoma in situ: The art of thinking counterintuitively.
    Eur J Cancer. 2022;168:138-140.
    >> Share

  109. SCHIZA A, Thurfjell V, Stenmark Tullberg A, Olofsson H, et al
    Tumour-infiltrating lymphocytes add prognostic information for patients with low-risk DCIS: findings from the SweDCIS randomised radiotherapy trial.
    Eur J Cancer. 2022;168:128-137.
    >> Share

    May 2022
  110. AMANT F, Nekljudova V, Maggen C, Seither F, et al
    Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls.
    Eur J Cancer. 2022;170:54-63.
    >> Share

  111. SHAGISULTANOVA E, Gao D, Callihan E, Parris HJ, et al
    Overall survival is the lowest among young women with postpartum breast cancer.
    Eur J Cancer. 2022;168:119-127.
    >> Share

    April 2022
  112. MASUDA N, Ono M, Mukohara T, Yasojima H, et al
    Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort.
    Eur J Cancer. 2022;168:108-118.
    >> Share

  113. MARTIN M, Zielinski C, Ruiz-Borrego M, Carrasco E, et al
    Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.
    Eur J Cancer. 2022;168:12-24.
    >> Share

  114. GOKER E, Hendriks MP, van Tilburg M, Barcaru A, et al
    Treatment response and 5-year distant metastasis-free survival outcome in breast cancer patients after the use of MammaPrint and BluePrint to guide preoperative systemic treatment decisions.
    Eur J Cancer. 2022;167:92-102.
    >> Share

    March 2022
  115. DELALOGE S, Dureau S, D'Hondt V, Desmoulins I, et al
    Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer.
    Eur J Cancer. 2022 Mar 22. pii: S0959-8049(22)00035.
    >> Share

  116. GAILLARD T, Carton M, Mailliez A, Desmoulins I, et al
    Corrigendum to "De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): characteristics and prognosis" [Eur J Cancer 158 (2021) 181-188].
    Eur J Cancer. 2022 Mar 18. pii: S0959-8049(22)00119.
    >> Share

  117. GELBER RD, Wang XV, Cole BF, Cameron D, et al
    Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY
    Eur J Cancer. 2022;166:219-228.
    >> Share

  118. VAN MACKELENBERGH MT, Seither F, Mobus V, O'Shaughnessy J, et al
    Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients.
    Eur J Cancer. 2022;166:185-201.
    >> Share

    February 2022
  119. LIU Z, Wang C, Chen X, Zhu J, et al
    Pathological response and predictive role of tumour-infiltrating lymphocytes in HER2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy (Panphila): a multicentre phase 2 trial.
    Eur J Cancer. 2022;165:157-168.
    >> Share

  120. WANG Y, Reulen RC, Kremer LCM, de Vathaire F, et al
    Male breast cancer after childhood cancer: Systematic review and analyses in the PanCareSurFup cohort.
    Eur J Cancer. 2022;165:27-47.
    >> Share

  121. DALENC F, Lusque A, De La Motte Rouge T, Pistilli B, et al
    Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study.
    Eur J Cancer. 2022;164:70-79.
    >> Share

  122. PECE S, Sestak I, Montani F, Tillhon M, et al
    Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy.
    Eur J Cancer. 2022;164:52-61.
    >> Share

  123. MALORNI L, Tyekucheva S, Hilbers FS, Ignatiadis M, et al
    Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.
    Eur J Cancer. 2022;164:39-51.
    >> Share

    January 2022
  124. VAN DER PLAS-KRIJGSMAN WG, Morgan JL, de Glas NA, de Boer AZ, et al
    Differences in treatment and survival of older patients with operable breast cancer between the United Kingdom and the Netherlands - A comparison of two national prospective longitudinal multi-centre cohort studies.
    Eur J Cancer. 2022;163:189-199.
    >> Share

  125. KARSTEN MM, Roehle R, Albers S, Pross T, et al
    Real-world reference scores for EORTC QLQ-C30 and EORTC QLQ-BR23 in early breast cancer patients.
    Eur J Cancer. 2022;163:128-139.
    >> Share

  126. TARANTINO P, Gandini S, Nicolo E, Trillo P, et al
    Evolution of low HER2 expression between early and advanced-stage breast cancer.
    Eur J Cancer. 2022;163:35-43.
    >> Share

  127. UGALDE-MORALES E, Grassmann F, Humphreys K, Li J, et al
    Interval breast cancer is associated with interferon immune response.
    Eur J Cancer. 2022;162:194-205.
    >> Share

    December 2021
  128. IWAMA E, Zenke Y, Sugawara S, Daga H, et al
    Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations.
    Eur J Cancer. 2021;162:99-106.
    >> Share

  129. PEUKER CA, Yaghobramzi S, Grunert C, Keilholz L, et al
    Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trial.
    Eur J Cancer. 2021;162:45-55.
    >> Share

  130. ALBANELL J, Martinez MT, Ramos M, O'Connor M, et al
    Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER).
    Eur J Cancer. 2021;161:26-37.
    >> Share

  131. JUAN Z, Chen J, Ding B, Yongping L, et al
    Probiotic supplement attenuates chemotherapy-related cognitive impairment in patients with breast cancer: a randomised, double-blind, and placebo-controlled trial.
    Eur J Cancer. 2021;161:10-22.
    >> Share

  132. GOLATTA M, Pfob A, Busch C, Bruckner T, et al
    The potential of combined shear wave and strain elastography to reduce unnecessary biopsies in breast cancer diagnostics - An international, multicentre trial.
    Eur J Cancer. 2021;161:1-9.
    >> Share

    November 2021
  133. PATSOURIS A, Diop K, Tredan O, Nenciu D, et al
    Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation.
    Eur J Cancer. 2021;159:283-295.
    >> Share

  134. CORTI C, Giachetti PPMB, Eggermont AMM, Delaloge S, et al
    Therapeutic vaccines for breast cancer: Has the time finally come?
    Eur J Cancer. 2021 Nov 22. pii: S0959-8049(21)01185.
    >> Share

  135. SCHNEEWEISS A, Michel LL, Mobus V, Tesch H, et al
    Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast
    Eur J Cancer. 2021 Nov 17. pii: S0959-8049(21)01164.
    >> Share

  136. HANNOUN-LEVI JM, Gutierrez C, Polgar C, Strnad V, et al
    Letter comments on: The impact of isolated local recurrence on long-term outcome in early-breast cancer patients after breast-conserving therapy.
    Eur J Cancer. 2021;159:224-226.
    >> Share

  137. VICIER C, Sfumato P, Isambert N, Dalenc F, et al
    TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients.
    Eur J Cancer. 2021;159:205-214.
    >> Share

    October 2021
  138. GAILLARD T, Carton M, Mailliez A, Desmoulins I, et al
    De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosis.
    Eur J Cancer. 2021;158:181-188.
    >> Share

  139. CAMPONE M, Bachelot T, Treilleux I, Pistilli B, et al
    A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial).
    Eur J Cancer. 2021;158:169-180.
    >> Share

  140. GARREFFA E, Hamad A, O'Sullivan CC, Hazim AZ, et al
    Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer care.
    Eur J Cancer. 2021;159:38-51.
    >> Share

    September 2021
  141. HAN MG, Jang BS, Kang MH, Na D, et al
    PI3Kgammadelta inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
    Eur J Cancer. 2021;157:450-463.
    >> Share

  142. DAVEY MG, Richard V, Lowery AJ, Kerin MJ, et al
    OncotypeDX(c) Recurrence Score in BRCA mutation carriers: a systematic review and meta-analysis.
    Eur J Cancer. 2021;154:209-216.
    >> Share

  143. GUARNERI V, Giorgi CA, Cinieri S, Bengala C, et al
    Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial.
    Eur J Cancer. 2021;154:21-29.
    >> Share

  144. HEIN A, Hartkopf AD, Emons J, Lux MP, et al
    Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status.
    Eur J Cancer. 2021;155:1-12.
    >> Share

    May 2021
  145. SAESEN R, Lacombe D, Huys I
    Design, organisation and impact of treatment optimisation studies in breast, lung and colorectal cancer: The experience of the European Organisation for Research and Treatment of Cancer.
    Eur J Cancer. 2021;151:221-232.
    >> Share

  146. MORENO-ASPITIA A, Holmes EM, Jackisch C, de Azambuja E, et al
    Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D).
    Eur J Cancer. 2021;148:287-296.
    >> Share

  147. CAMPANALE A, Di Napoli A, Ventimiglia M, Pileri S, et al
    Chest wall infiltration is a critical prognostic factor in breast implant-associated anaplastic large-cell lymphoma affected patients.
    Eur J Cancer. 2021;148:277-286.
    >> Share

  148. VOS H, Lambein K, Wildiers H, Punie K, et al
    Immune-related adverse events after a single dose of pembrolizumab.
    Eur J Cancer. 2021;148:92-94.
    >> Share

    March 2021
  149. PUJOL P, Barberis M, Beer P, Friedman E, et al
    Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
    Eur J Cancer. 2021;146:30-47.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016